William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on TransMedics Group (TMDX – Research Report). The associated price target remains the same with $104.00.
William Plovanic has given his Buy rating due to a combination of factors that highlight TransMedics Group’s strong market position and growth potential. The company has demonstrated a significant increase in the donation after circulatory death (DCD) liver transplants, which have grown by 52% year-over-year, showcasing its leadership in this segment with a substantial market share. This growth trajectory is supported by robust year-over-year increases in DCD heart and liver transplants, reinforcing the company’s ability to expand the overall organ transplant market.
Furthermore, Plovanic notes that despite some month-over-month declines, the overall quarter-to-date trends remain positive, aligning with expectations for a solid performance in Q1/25. The company’s strategic adjustments, including capturing additional revenue streams from clinical trial patients utilizing the OCS system, further enhance its financial outlook. These factors combined suggest that TransMedics is well-positioned for continued success, justifying the Buy rating and maintaining a price target of $104.
According to TipRanks, Plovanic is a 3-star analyst with an average return of 1.7% and a 42.83% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, CVRx, and Boston Scientific.
In another report released on March 4, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.